The gram-negative bacterium Yersinia pestis is the etiological agent of plague and is classifie as a category A pathogen that is a potential agent of bioterrorism [1, 2] . There are 3 forms of the human disease: bubonic, septicemic, and pneumonic [2, 3] . Of these, the pneumonic plague is of most concern as a biological threat, because of the rapid onset, high mortality, and rapid spread. Although antibiotics can successfully treat plague, the fatality rate is high when treatment is delayed 124 h after the onset of symptoms [2] [3] [4] . At present, no plague vaccines are available in the United States. Several vaccines have been developed, including killed whole-cell formulations and the live attenuated EV76 vaccine [5] [6] [7] [8] . Although these vaccines have been used in humans, they offer low levels of protection, have numerous adverse side effects, and require frequent immunizations with consequent prolonged time to develop immunity [5] [6] [7] [8] . A promising subunit vaccine is based on the virulence (V) antigen (also referred to as "LcrV") [9] [10] [11] . V antigen is a 37-kDa multifunctional protein of Yersinia species encoded by the 70-kb low calcium response (lcr) plasmid. V antigen participates in the type III secretion system in Y. pestis regulating the production and facilitating the translocation of Yersinia outer proteins (Yops) with anti-host activity into the host cell [12, 13] . Active immunization with purifie V antigen or passive immunization with antiserum against V antigen provides protection against plague in mice [9, 10, 14, 15] . V antigen-based DNA vaccines are also being developed [16, 17] . These vaccines elicit low antibody titers, and
At present, no plague vaccines are available in the United States. Several vaccines have been developed, including killed whole-cell formulations and the live attenuated EV76 vaccine [5] [6] [7] [8] . Although these vaccines have been used in humans, they offer low levels of protection, have numerous adverse side effects, and require frequent immunizations with consequent prolonged time to develop immunity [5] [6] [7] [8] . A promising subunit vaccine is based on the virulence (V) antigen (also referred to as "LcrV") [9] [10] [11] . V antigen is a 37-kDa multifunctional protein of Yersinia species encoded by the 70-kb low calcium response (lcr) plasmid. V antigen participates in the type III secretion system in Y. pestis regulating the production and facilitating the translocation of Yersinia outer proteins (Yops) with anti-host activity into the host cell [12, 13] . Active immunization with purifie V antigen or passive immunization with antiserum against V antigen provides protection against plague in mice [9, 10, 14, 15] . V antigen-based DNA vaccines are also being developed [16, 17] . These vaccines elicit low antibody titers, and protection against a Y. pestis challenge is reached only after several immunizations [18] .
The present study is focused on using replication-deficien adenovirus (Ad) gene-transfer vectors encoding V antigen to elicit protective immune responses against Y. pestis. Ad vectors are excellent candidates for vaccine platforms as they transfer genes effectively to antigen-presenting cells (APCs) in vivo, with consequent activation of APCs, thus conveying immune adjuvant properties and inducing strong, rapid humoral and cellular immune responses against the transgene product [19] [20] [21] [22] [23] [24] [25] [26] . On the basis of these considerations, we constructed an E1 Ϫ E3
Ϫ Ad-based vaccine vector that encodes a secreted human codonoptimized V antigen (AdsecV). The data demonstrate that AdsecV induces high IgG titers within 2 weeks after a single intramuscular immunization in mice. Importantly, mice immunized with a single intramuscular dose of AdsecV are protected from a lethal intranasal challenge of Y. pestis.
METHODS

Ad vectors.
The Y. pestis V antigen gene (NCBI accession no. B33601) with mammalian-preferred codons was synthesized by overlap polymerase chain reaction and fused to the human Igk signal sequence for extracellular secretion. The V antigen gene was cloned into a recombinant Ad5-based vector (E1a, partial E1b, and partial E3 deletion), to generate AdsecV. AdNull was used as a control vector with identical backbone but no transgene [27] . The vectors were produced in 293 cells and were purifie by double CsCl gradient centrifugation [28] . Dosing was based on particle units (pu), the physical number of Ad particles as measured by spectrophotometry [29] . Purificatio of recombinant V antigen. Recombinant V antigen was produced as a reagent for assessment of antibodies against V antigen. The V antigen gene was cloned into the pRSET expression plasmid (Invitrogen), and V antigen was purifie as a histidine-tag fusion by use of a Ni-NTA Superflo Column (Qiagen) under native conditions. Expression of V antigen by AdsecV in vitro. The A549 lung epithelial cell line (CCL185; American Type Culture Collection) was maintained in complete Dulbecco's modifie essential medium. Cells were infected with AdsecV or AdNull (500 pu/cell) in low-serum medium. Twenty-four hours after infection, cells and medium were collected, and proteins were separated by SDS-PAGE (Invitrogen) and transferred to a polyvinylidene fluorid membrane (BioRad Laboratories). For Western blot analysis, the membrane was probed with a 1:1000 dilution of a rabbit anti-V antigen antibody (provided by S. Bavari, US Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD). A peroxidase-conjugated anti-rabbit antibody (Santa Cruz Biotechnology) and a chemiluminescent peroxidase substrate (ECL+ reagent; Amersham Biosciences) were used for detection.
To assess V antigen expression by immunofluo escence, 24 h after infection, cells were fixe with 4% paraformaldehyde and blocked with 5% goat serum (Jackson ImmunoLabs), 1% bovine serum albumin in PBS with 0.05% saponin (SigmaAldrich), and 0.1% Triton X-100 (Sigma-Aldrich), followed by incubation with the rabbit anti-V antigen antibody diluted 1: 1000. A goat anti-rabbit secondary antibody conjugated to Alexa 488 fluo ophore (Jackson ImmunoLabs) was used at a fina concentration of 10 mg/mL. Nuclei were counterstained with 4 ,6-diamidino-2-phenylindole (Molecular Probes). The samples were observed by fluo escence microscopy with an Olympus IX70 inverted microscope (New York/New Jersey Scientific equipped with a ϫ60 PlanApo NA 1.4 objective, and digital image analysis was performed with Metamorph imaging software (version 4.6r9; Universal Imaging).
Mice. Female BALB/c mice were obtained from Taconic. Mice were housed under specific-pathogen-f ee conditions and were used at 7 weeks of age. Mice were immunized in a single vaccination by 2 intramuscular injections, with 50 mL of the vaccine preparation divided evenly between the quadriceps on each side. Ad vectors were diluted with saline to the specifie dose.
Transgene-specifi humoral responses. Serum samples from immunized mice were obtained from the tail vein, and anti-V antigen serum antibody titers were determined by ELISA. For vector dose response, serum samples were obtained from mice 4 weeks after immunization with AdsecV at doses ranging from 10 8 to 10 11 pu. For time-dependent anti-V antigen antibody titers, mice were immunized with a single administration of 10 9 pu of AdsecV, and serum samples were obtained before and at 1, 2, 4, 6, and 8 weeks after vaccination. For IgG subtypes, mice were vaccinated with 10 9 pu of AdsecV, and serum samples were obtained 5 weeks after immunization.
For ELISAs, microtiter plates (Corning) were coated with 0.5 mg of recombinant V antigen per well. After blocking, serum samples were added in sequential 2-fold dilutions starting at 1:20 and were incubated for 1 h at 23ЊC. An anti-mouse IgGhorseradish peroxidase conjugate (Sigma-Aldrich) was used at 1:10,000 dilution. Detection was accomplished using a peroxidase substrate (BioRad Laboratories). Absorbance at 415 nm was read using a microplate reader (BioRad Laboratories). Classspecifi anti-IgG antibodies (IgG1, IgG2a, IgG2b, and IgG3) were determined using the Mouse Typer isotyping panel (Bio-Rad Laboratories). Antibody titers were calculated on the basis of a log(optical density) Ϫ log(dilution) interpolation model and a cutoff value equal to 2-fold the absorbance of the background [30, 31] .
Transgene-specifi cellular responses. Mice were immunized intramuscularly ( ) with either saline, AdNull (10 11 n p 5 pu), or AdsecV (10 11 pu). The frequency of antigen-specifi T lymphocytes was determined using an interleukin (IL)-2-, in- 
terferon (IFN)-g-, and IL-4-specifi enzyme-linked immunospot (ELISPOT) assay (R&D Systems). Six days after administration of Ad, CD4
+ or CD8 + T cells were purifie by negative depletion using SpinSep T cell subset purificatio kits (StemCell Technologies). Splenic dendritic cells (DCs) were purifie from naive mice by positive selection using CD11c MACS beads (Milentyi Biotec) and double purificatio over 2 MACS-LS columns (Milentyi Biotec). The purity of CD4 + T cells, CD8 + T cells, and DCs was assessed by staining with anti-CD4-phycoerythrin (PE), anti-CD8-PE, and anti-CD11c-PE antibodies (BD Biosciences), respectively. Cell purity evaluation and cell counts were performed using a FACScalibur flo cytometer running at a constant flo rate. For ELISPOT assays, 10 5 CD4 + or CD8 + T cells were incubated for 36 h with splenic DCs at a ratio of 4:1, with or without purifie V antigen. Spots were counted by computer-assisted ELISPOT image analysis (Zellnet Consulting).
Y. pestis CO92 challenge. The Y. pestis challenge studies were conducted at the Public Health Research Institute at the International Center for Public Health under biosafety level 3 conditions. Four weeks or 6 months after immunization, mice (10/group) were challenged intranasally with Y. pestis CO92. Y. pestis CO92 was grown aerobically in heart infusion broth (Difco) at 30ЊC and was diluted in saline solution at doses ranging from 10 3 to 10 6 cfu. Fifty microliters of bacterial suspension was used for intranasal infection of mice. Bacterial dose was controlled by plating on Yersinia selective agar (YSA; Oxoid). Survival was monitored daily for 15 days. From a subset of the mice that died after challenge, liver, spleen, and lungs were removed, homogenized in saline solution, and plated on YSA, to confi m that plague was the cause of death. A subset of the vaccinated mice that survived the challenge were killed 15 days after infection; liver, spleen, and lungs were removed, homogenized in saline solution, and plated on YSA to confi m that bacteria were not present in internal organs.
Statistical analyses. Data are presented as valmean ‫ע‬ SE ues. For ELISPOT assays, statistical analyses were performed using 1-way analysis of variance followed by Fisher's protected least significan difference test. For survival comparison, Kaplan-Meier analysis was performed; reported P values are from Mantal-Cox analysis. Statistical significanc was determined at . P ! .05
RESULTS
Expression of V antigen by AdsecV. V antigen expression by
AdsecV was analyzed in vitro by Western blot analysis. Twentyfour hours after infection of A549 cells with AdsecV, a protein with the expected size for V antigen (37 kDa) was identifie in medium and cell lysates by use of an anti-V antigen antibody (figu e 1A). The protein was not detected in cells infected with AdNull (the control vector) or in uninfected cells. The localization of V antigen in the AdsecV-infected cells was evaluated by indirect immunofluo escence. At 24 h, V antigen (figu e 1C) exhibits a broad, diffuse staining pattern as well as a bright, punctate, perinuclear staining pattern consistent with localization of V antigen in the endoplasmic reticulum and Golgi apparatus of the secretory pathway. The protein was not present in AdNull-infected cells (figu e 1B).
Humoral immune responses to AdsecV. To evaluate hu- To evaluate the kinetics of the anti-V antibody response, total IgG titers were measured at different time points after a single vaccination. After administration of a 10 9 -pu dose of AdsecV, anti-V antigen titers were detected in serum of immunized mice as early as 1 week (figu e 2B). The antibody titer reached a maximum level at 2 weeks and remained high through 8 weeks. Analysis of IgG subclasses at the 10 9 -pu AdsecV dose showed a strong response for both IgG1 and IgG2a and a lesser response for IgG2b and IgG3 (figu e 2C). Similar antibody titers and subtypes were observed with an Ad vector expressing a nonsecreted form of V antigen (data not shown). Anti-V antigen antibody after immunization with 10 9 pu of the nonsecreted form could be detected in serum at 2 weeks, with a titer of . Antibody levels remean ‫ע‬ SE 13,700 ‫ע‬ 2,900 mained high through week 8, as reported for AdsecV (figu e 2B). Because anti-V antigen antibodies in serum could already be detected 1 week after immunization with AdsecV and because titers were similar for both forms of the vaccine, we focused our study on the responses evoked by AdsecV.
Cellular immune responses to AdsecV. The frequency of T cell responses to V antigen in vaccinated mice was analyzed by ELISPOT assay. Six days after mice were immunized with 10 11 pu of AdsecV, purifie CD4 + and CD8 + T cells from the spleens of the vaccinated mice were stimulated with syngeneic DCs pulsed with V antigen, and cytokine production was assessed. Mice were immunized intramuscularly with either saline (naive mice), the control vector AdNull (10 11 + T cells from the AdsecV-immunized mice than in the 2 control groups. In contrast, no significan differences were observed for V antigen-specifi IL-4 production (figu e 3B). CD8 ) (figu e 5A). The survival P ! .005 of mice that were immunized with 10 10 pu of AdsecV ranged from 40% (4/10; ) (figu e 5A) to 60% (6/10) in a dif-P ! .05 ferent experiment (data not shown). The 10 9 -and 10
8
-pu doses were not protective; the mice in those groups died according to the same time frame as did the mice in the control groups that received either saline or 10 11 pu of AdNull. Assessment of the data at 15 days after challenge showed that the mortality of mice was dependent on the vaccine dose (figu e 5B).
To evaluate the protective capacity of the vaccine at different challenge doses, mice were infected intranasally with 10 3 -10 6 cfu of Y. pestis CO92 4 weeks after a single administration of 10 11 pu of AdsecV. Mice were protected at all doses (figu e 6). All AdsecV-immunized mice (10/10) survived the challenge with 10 3 ( ) and 10 4 ( ) cfu, whereas the naive P ! .005 P ! .0001 mice and the mice immunized with 10 11 pu of AdNull died within 3-5 days. At higher challenge doses, 80% (8/10) and 90% (9/10) of the mice survived after intranasal infection with 10 5 and 10 6 cfu Y. pestis CO92, respectively ( ).
The capacity of the vaccine to confer long-term protection was evaluated by challenge at 6 months after a single immunization with 10 11 pu of AdsecV. Anti-V antigen total IgG titers in immunized mouse serum before challenge were a mean ‫ע‬ of ( ). Mice were infected intra-SE 106,000 ‫ע‬ 16,500 n p 20 nasally with 10 4 or 10 6 cfu of Y. pestis CO92. All AdsecV-immunized mice (10/10) survived the challenge with 10 4 cfu and 90% (9/10) survived the challenge with 10 6 cfu ( , for P ! .0001 both doses) (figu e 7), whereas none of the 10 naive mice survived the challenge with 10 4 cfu Y. pestis CO92.
DISCUSSION
In the present study, AdsecV, a replication-defective Ad vector expressing a secreted form of the Y. pestis V antigen, was evaluated as a vaccine against plague. The V antigen sequence in AdsecV was targeted for extracellular expression by an Igk Y. pestis vaccines. Plague is one of the most devastating acute infectious diseases experienced by humankind [1] [2] [3] [4] [5] . Antibiotics are only marginally effective once symptoms of pneumonic plague develop; moreover, some antibiotic-resistant isolates have been identified Given these characteristics, there is concern that an aerosolized form of Y. pestis may be exploited as a bioweapon.
There is no licensed Y. pestis vaccine for use in the United States. Killed whole-cell vaccines have been used since the late 1890s [5] [6] [7] [8] . Although these vaccines have been shown to protect against the bubonic form of the disease, they do not protect against pneumonic plague. These vaccines also have disadvantages, such as a significan incidence of transient local and systemic adverse side effects and the need for frequent boosting to maintain adequate immunity [5, 7, 8] . A live attenuated vaccine based on the pigmentation-negative Y. pestis strain EV76 has been available since 1908 [6] . This vaccine had questionable efficac in evoking effective immune responses in humans and presents the risk for reversion to virulence in vivo.
In recent years, the development of a safe and effective plague vaccine has been focused on using recombinant protein subunits of Y. pestis [5, [9] [10] [11] . Several virulence factors have been identifie as possible vaccine candidates, but the most promising are the V antigen and the F1 protein [7] [8] [9] [10] [11] [32] [33] [34] . Antibodies against V and F1 confer protection against both bubonic and pneumonic plague in mice, guinea pigs, and nonhuman primates [9-11, 14, 15, 33, 35] . Recent studies have shown that a single intramuscular immunization with both recombinant antigens delivered with adjuvants and combined in a molar ratio of 2:1 (F1:V antigen) protected mice against an aerosol challenge with Y. pestis [10, 11, [36] [37] [38] [39] . Although this protection was correlated with high IgG levels [40] , it has been suggested that nonhumoral immune responses also participate, because immunized IL-4-deficien mice, which do not mount effective humoral immune responses, have been shown to be protected against plague [41] . Also, immunization with the combined subunits failed to protect signal transducer and activator of transcription (Stat) 4 [12, 13, 45, 46] . In addition, purifie V antigen has been shown to suppress the normal inflammato y response in the host by down-regulating the expression of tumor necrosis factor (TNF)-a and IFN-g, which promotes the production of IL-10 by macrophages, and by inhibiting the chemotaxis of neutrophils [47] [48] [49] [50] .
The basis for the protection conferred by the recombinant V antigen vaccine is not well known. The correlation with high IgG titers and protection of immunodeficien SCID/Beige mice against pneumonic plague by passive transfer of anti-V antigen-specifi immune serum [14, 15, 51] suggests that anti-V antigen antibodies play a significan role. It has been shown that anti-V antigen antibody administered during infections of mice with Y. pestis restore the production of TNF-a and IFNg [49] , and in vitro assays have shown that anti-V antigen antibodies can partially block the delivery of Yops (and the consequent downstream effects of Yops) in infected macrophage-like cells [52] . Thus, the protection conferred by a V antigen vaccine might be achieved by opsonization through antibody association with surface V antigen on Y. pestis, by blocking the delivery of Yops to host cells, by preventing early bacterial growth in macrophages, and/or by neutralizing the immunomodulatory activity of V antigen, allowing the host to mount an inflammato y response.
Ad vectors as vaccine platforms. Recombinant Ad vectors are attractive for vaccine strategies against pathogens for many reasons. They are stable, easy to manipulate, can be produced inexpensively at high titer, and can be purifie by commonly available methods [53] . Ad vectors are capable of delivering genes to a broad variety of cell types, and relevant to their use as a vaccine is their ability to infect DCs and other APCs in vivo. The Ad vector itself may act as adjuvant by inducing a strong inflammato y response at the injection site and by promoting the differentiation of immature DCs into professional APCs [54] [55] [56] . Recombinant Ad vectors expressing a wide variety of pathogen-specifi genes have been used in vaccination studies in rodents, canines, and nonhuman primates [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] . Ad vectors induce protective adaptive immune responses against the transgene product very rapidly after a single application [19] [20] [21] [22] [23] [24] [25] [26] . This feature is particularly useful for postexposure vaccination or to combat infectious agents that cause infrequent but rapidly spreading outbreaks associated with high mortality.
The present evaluation of the efficac of an Ad vaccine, AdsecV, expressing the Y. pestis V antigen demonstrated the induction of rapid protective humoral and cellular immune responses. AdsecV antibody responses were elicited rapidly (within 2 weeks after administration) and showed the characteristic Th1/Th2 responses elicited by Ad vectors. Most importantly, the immune responses evoked by AdsecV were sufficien to protect immunized mice against an intranasal challenge with a fully virulent strain of Y. pestis. Together, these data suggest that AdsecV is a promising vaccine candidate for protection against plague.
